Professor of Old Age Psychiatry King's College London Institute of Psychiatry NIHR Biomedical Research Centre of Mental Health MRC Centre for Neurodegeneration Research De Crespigny Park London SE5 8AF s.lovestone@iop.kcl.ac.uk
Centre for Imaging and Biomarkers
Programme leadership
Professor Simon Lovestone
Programme members
Programme Management Group and pilot project leads
Dr Alison Campbell King’s College London
Dr Ian Pike Proteome Sciences
Edwina Wright Programme Consultant
Dr David Parry South East Health Trust Association
Professor Dave Hawkes Imaging working party; University College London
Professor Chris Lowe ‘omics working party; Cambridge
Professor Graham Lord Informatics working party; Imperial College, London
Dr Christina Legido-Quigley Metabonomics of dementia project; King’s College London
Professor Jeremy Nicholson Metabonomics of dementia project; Imperial College London
Professor Shitij Kapur Markers of schizophrenia project; King’s College London
Professor Sabine Bahn Markers of schizophrenia project; Cambridge
Professor Nick Fox Multi-site neuroimage management project; Institute of Neurology
Professor Peter Jezzard Multi-site neuroimage management project; FRIMB Centre, John Radcliffe Hospital
Professor Derek Hill Multi-site neuroimage management project; Ixico
Colleagues from Lilly UK, Pfizer and GSK provided input into project development as below:
Dr Chas Bountra GlaxoSmithKline
Dr Jackie Hunter GlaxoSmithKline
Dr David Bowman Lilly
Dr Andrew Wood Lilly
Dr Mike Hutton Lilly
Dr Ruth McKernan Pfizer
Related news
Centre for Imaging and Biomarkers progress update
A business plan is under discussion to provide a Centre for Imaging and Biomarkers (CIB) of global significance, to advance the development of personalised medicine in drug development and in clinical practice.
30 Oct '09Established methods of drug development have become less productive in delivering highly effective and safe new medicines, particularly for diseases, such as the neurodegenerative diseases and cancer. A strategic review by the European Federation of Pharmaceutical Industries Association (EFPIA) in 2004 concluded that one of the main obstacles to the development of drugs was the relative paucity of biomarkers for use in clinical trials as markers of toxicity, of disease response and as surrogate endpoints. At the same time, physicians require better diagnostics tools especially in the early signs of disease when treatment is likely to be more successful and where it may require less aggressive dosing regimes. Looking ahead, biomarkers are the essential component of the much anticipated era of personalised medicine.
The challenge is to provide effective and standardised methods for the timely development of biomarkers that can be adapted to deliver accurate and reproducible assays suitable for routine use in clinical trials and in patient management. This has the potential to substantially reduce the time and cost of drug development, accelerate patient diagnosis and improve treatment outcomes. The proposition is that by linking the expertise, infrastructure and access to patient populations in the Greater South East Region’s universities, hospitals, pharmaceutical and diagnostics industries in a globally-competitive cluster, we could achieve these ambitious goals.
The Centre for Imaging and Biomarkers (CIB) will build on existing partnerships to establish the Greater South East of England as the premier centre for imaging and biomarker research and translation. All partners in the consortium have expertise in imaging, biomarkers, enabling technologies, bioinformatics and/or co-ordination of large clinical evaluations of biomarkers in neuroscience and specifically Alzheimer’s disease. In addition there are other groups within the CIB consortium actively seeking biomarkers in other neurological diseases and, in line with the Innovative Medicines Initiative priorities, in other disease areas. Once established, the GMEC CIB intends to expand its activities to progress imaging and biomarker development in additional disease areas, including, oncology, immunity and cardiovascular diseases
